Opko Health (OPK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Opko Health

NasdaqGS•Healthcare•Diagnostics & Research

$1.64+0.03(0.02%)Market closed

Market Cap

$1.19B

P/S

2.0x

P/B

1.0x

OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune system. This segment also engages in the development of Epstein Barr Virus vaccine; Rayaldee, a patented extended-release product for oral administration containing 30 mcg of a prohormone; OPK-88006 oral and injectable product to regulate blood glucose and reduce body weight; NGENLA, recombinant human growth hormone product developed for the long-term treatment of pediatric patients with growth hormone deficiency. The Diagnostics segment offers laboratory testing services, such as detection, diagnosis, evaluation, monitoring, and treatment of diseases, as well as esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare under the BioReference brand; and 4Kscore test. OPKO Health, Inc. was founded in 2006 and is headquartered in Miami, Florida.

How this company scores

WeakMetricSide Score: 46/100

Grade capped at D — Interest coverage below 1× (-1.1x) — earnings cannot cover interest. Strongest: Profitability (17/25); weakest: Cash & Earnings Quality (6/25).

Profitability17/25

Growth6/25

Balance Sheet & Red Flags17/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayLow leverageProfit converts from growthImproving leverage

Grade capped at D

Interest coverage below 1× (-1.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 31.2x5y range 31.2x – 31.2x

P/S · 2.0x5y range 0.9x – 2.0x

Currently above its 20-quarter median.

P/B · 1.0x5y range 0.6x – 1.9x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $1.19B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $587.90M
Q. Revenue: $163.58M
TTM EBITDA: $41.47M
TTM Op. Income: $-48.25M
Q. Op. Income: $-6.97M
TTM Net Income: $-72.89M
Q. Net Income: $-8.42M
EPS: $-0.01
Shares Out.: $755.27M

$587.90M in TTM revenue declined 11.5% YoY, reaching $163.58M last quarter. TTM EBITDA of $41.47M and TTM operating income of $-48.25M show growth is flowing through to the bottom line. However, net income is negative at $72.89M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 11% — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 48.9%
EBITDA Margin: 9.4%
Op. Margin: -4.3%
Net Margin: -5.1%

Op. margin of -4.3% is up 34.0% YoY — cost efficiency is improving. Net margin at -5.1% and gross margin of 48.9% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 89% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 2.0x
P/B Ratio: 1.0x

P/S of 2.0x and P/B of 1.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $1.83B
Cash: $300.76M
Long-Term Debt: $1.78M
Book Value: $1.18B
D/E Ratio: 0.0
Debt/EBITDA: 0.1

With $1.83B in assets and $1.78M in long-term debt, D/E is 0.0and book value is $1.18B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 7 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-43.50M
TTM Free Cash Flow: $-134.02M
FCF Margin: -22.8%
FCF / Net Income: 1.8

TTM FCF of $-134.02M on $-43.50M in operating cash flow. The FCF / Net Income ratio of 1.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has risen for 3 consecutive quarters — an improving trend.